SPS
NPCE icon

Susquehanna Portfolio Strategies’s Neuropace NPCE Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$354K Buy
+22,279
New +$359K 0.01% 725

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Susquehanna Portfolio Strategies's NPCE Position: Q2 2026 in Review

Susquehanna Portfolio Strategies opened a new position in Neuropace (NPCE) in Q2 2026: 22,279 shares worth $354K. The stake represents 0.01% of the portfolio and ranks #725 among its holdings.

113 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Susquehanna Portfolio Strategies held 22,279 shares of Neuropace worth $354K as of Q2 2026.
  • Neuropace was a new Susquehanna Portfolio Strategies position in Q2 2026.
  • Neuropace made up 0.01% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #725 holding.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.